Articles Articulating the Problem
Share |

Tufts Center for the Study of Drug Development IMPACT Report

Volume 20, Number 5 – September/October 2018

Analysis & Insight into Critical Drug Development Issues

 

Neuron. 2014 Nov 5;84(3):554-63. doi: 10.1016/j.neuron.2014.10.027. Epub 2014 Nov 5.

Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Choi DW1, Armitage R2, Brady LS3, Coetzee T4, Fisher W5, Hyman S6, Pande A7, Paul S8, Potter W3, Roin B9, Sherer T10.

 

Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3.

Trends in risks associated with new drug development: success rates for investigational drugs.

DiMasi JA1, Feldman L, Seckler A, Wilson A.

 

Neuron. 2013 Oct 30;80(3):561-7. doi: 10.1016/j.neuron.2013.09.041.

Twenty-five years of progress: the view from NIMH and NINDS.

Insel TR1, Landis SC.

 

Is Pharma Running Out of Brainy Ideas?

Greg Miller

Science  30 Jul 2010:
Vol. 329, Issue 5991, pp. 502-504

 

The full cost and burden of disorders of the brain in Europe exposed for the first time

David J. Nutt

Imperial College, London, United Kingdom

 

Int J Neuropsychopharmacol. 2013 Aug;16(7):1687-93. doi: 10.1017/S1461145713000345. Epub 2013 May 7.

The current development of CNS drug research.

Wegener G1, Rujescu D.

 

The Burden of Neurological Disease in the United States: A Summary Report and Call to Action (2017).

American Neurological Association

 

Neuroscience Investment: Challenges & Outlook.  Presentation at the annual Biotechnology Industry Organization meeting.

Munro, J. (2018). 

 

Estimation of clinical trial success rates and related parameters.

Biostatistics, kxx069. Heem Wong, C., Wei Saih, K., & Lo, A.W. (2018)

American Brain Coalition

P.O. Box 1549 | Maple Grove, MN 55311 | Phone: (763) 557-2913